Navaux

Abstract 1177: Prognostic implications of circulating Hepsin in prostate cancer. AbstractIntroduction. and Objective: Hepsin, a type II transmembrane serine protease, has been implicated in prostate tumor progression and metastasis. Recent studies have uncovered its proteolytic auto-activation and ectodomain shedding, supporting its potential as a circulating serum biomarker. We...

10 years of data in prostate cancer…you can’t rush the science…so we waited…hoping…believing…that one day…we could improve the lives of patients. Accepted publication!

Stay TUNED….Q1 2026!!!

https://www.linkedin.com/posts/don-e-fowler-72098812_early-cancer-diagnostic-testing-results-activity-7282818346712973313-ifa4?utm_source=share&utm_medium=member_desktop

Don E. Fowler on LinkedIn: **Early cancer diagnostic testing results from Navaux look very… **Early cancer diagnostic testing results from Navaux look very promising!** We've found new ways to detect tumor development in patients before most molecular…

https://arprostatecancer.org/events/pigskins-prostates-golf-tournament-rogers/

Pigskins & Prostates Golf Tournament - Rogers - Arkansas Prostate Cancer Foundation We are excited to re-introduce Pigskins and Prostates Golf and grow an annual golf tournament once again in Northwest Arkansas.

Calling all bourbon lovers and thrill-seekers! The Beards & Blue Ribbons Event is happening on September 19th at Chenal Country Club, and it’s going to be an evening to remember. Sip on exclusive bourbons, try your hand at fly-casting and axe throwing, and get a fresh trim from Morrison’s Capitol Barber Shop. Don’t forget to check out our text-to-bid auction—there’s something for everyone! 🍻🎯

Get your tickets today! https://my.onecause.com/event/organizations/a7645df5-6b3d-4144-ab1d-b9f966167a99/events/vevt:13d03164-6f3b-4164-9c16-718de5d5f2a0/home/story

When you say your monoclonal antibody is different and you have the EPITOPE MAPPING to prove it! Thanks to the entire team at Navaux for delivering on real scientific discovery!

🚀 Years Of Research At Navaux Begins To Redefine Hepsin's Role In Cancer Genesis 🚀

At Navaux, we’re on a mission to revolutionize cancer detection with our cutting-edge research in non-invasive early detection. We’re thrilled to share a major breakthrough in our work with serine proteases, particularly hepsin.
While many have explored hepsin before, our team has uncovered critical differences between full-length hepsin and circulating, activated hepsin—insights that had eluded others. This discovery is a significant step forward in understanding cancer biomarkers and improving early detection methods.
We’re proud to announce that we’ve completed epitope mapping and filed patents for our innovative findings related to hepsin. This advancement brings us closer to transforming how cancer is detected and treated, ultimately paving the way for better patient outcomes.
A huge thank you to our dedicated team for their hard work and perseverance. We’re excited about the future and the potential impact of our discoveries!
🔬💡 Stay tuned for more updates as we continue to advance the field of cancer research.
hashtag hashtag hashtag hashtag hashtag hashtag hashtag

We just went live with our new website! Please check out what we are doing in our cancer fight!

Navaux Early Cancer Detection Diagnostics

NAVAUX PRESENTS PRE-CLINICAL AND CLINICAL CIRCULATING HEPSIN DATA AT THE 2020 AACR ANNUAL MEETING

June 8, 2020 –Navaux announces today that new pre-clinical and clinical data evaluating the prognostic potential of circulating Hepsin have been selected for presentation at the American Association for Cancer Research (AACR). The poster presentation is now available online.

For greater than a decade, Hepsin has been known to play a key role in prostate cancer development and progression. However, most of these studies were aimed at the gene expression level as detection of the protein itself rendered more questions than clinically actionable findings. This inability to consistently and reliably detect Hepsin at the protein level stems from traditional antibody development approaches that targeted a tumor-naïve, inactivated form of Hepsin. Hepsin in cancer, as we now understand from recent studies, exists as a soluble, circulating molecule.

Scientists at Navaux have successfully overcome prior issues surrounding the detection of activated circulating Hepsin in the bodily fluids. The resulting liquid biopsy has undergone rigorous analytical validation and is now being used prospectively at the time of biopsy as a longitudinal means of early metastasis detection/risk stratification as well as response to treatment.

“It’s an honor to present at the annual AACR meeting; presentation of clinical data at a meeting of this caliber provides multiple avenues for discussion and further collaborative thought” said Dr. Blake Johnson, Chief Scientist and Director at Navaux. “As we continue to evaluate circulating Hepsin as a prognostic marker for prostate cancer, and broaden our research to understand its biological impact on disease progression, we are pleased to highlight data that link the therapeutic potential of circulating Hepsin to difficult-to-treat prostate cancer.”

Below is a brief description of the abstract accepted publication at this year’s AACR Annual Meeting.

Title: Circulating Hepsin as a Novel Serum Biomarker in Prostate Cancer Patients

Authors: John Beard1, Sam Eddington2, Noah Bowman2, Adam Cole3, Timothy O’Brien1 and Blake P. Johnson1,2

Navaux, Inc., Little Rock, AR1

Ouachita Baptist University, Arkadelphia, AR2

Arkansas Urology, Little Rock, AR3

Navaux, Inc. adds Brent Staggs, M.D. to Advisory Board

Navaux, Inc. announced today, the addition of Brent Staggs to its Advisory Board. Dr. Staggs graduated Magna cm Laude from Ouachita Baptist University and received his Doctor of Medicine, from the University of Arkansas College of Medicine. After completing his residency in Pathology, he completed Fellowships in Hematopathology and Gastrointestinal Pathology at University of Arkansas for Medical Sciences. He has special training in Molecular Pathology, Pulmonary Pathology and Dermatopathology. Dr. Staggs is board certified in Anatomic, Clinical, and Hematology and is a Certified Medical Review Officer. In addition to being a well-respected guest lecturer throughout the country, he is well published in the field of cancer. Dr. Staggs maintains practice membership with Pathology Laboratories of Arkansas, P.A. who currently provide pathology services to Baptist Health throughout Arkansas. “Dr. Staggs brings a wealth of knowledge related to solid tumors in the clinical setting. This will provide Navaux with uncompromised direction as we pursue our mission of uncovering and treating cancer in its earliest stage.” – Don Fowler, CEO

Arkansas Researchers Develop Blood Test to Detect Early-Stage Cancer Researchers at Stage 1 Diagnostics in Little Rock have developed a blood test that can detect early-stage cancer by measuring a patient's levels of hepsin,